Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Guggenheim’s Randall Barnes Rescuing Its Stock Price?

Guggenheim, Randall Barnes: Randall C. Barnes, Director at Guggenheim Credit Allocation Fund (NYSE:GGM), purchased 4,000 shares of common stock in four separate transactions earlier this week, with prices varying from $23.35 to $23.50 for an estimated total of $93,650. All 4,000 shares will remain under the indirect control of Mr. Barnes.

Guggenheim Credit Allocation Fund

Barnes has bought the stock through the past two months with great intensity. There are three transactions registered under his name for the month of September, adding up to 3,430 shares of common stock for an average price of $23.51 each. For the current month of October, Mr. Barnes has registered five additional transactions for a total of 4,200 shares of common stock at an average price of $23.56 each.

The total shares under indirect control of Mr. Barnes add up to 7,700. His vehicle, Children’s Trust #1, controls 3,100, Deborah Barnes Roth controls 2,000, and Dean Barnes Roth controls the remaining 2,600.

The transactions have not been isolated, since Mr. Barnes holds a history for buying stock from the Guggenheim Credit Allocation. Since the beginning of August, the stock’s price has dropped from $25 to an all-time low of $23.31 on September 9th. Recovery since then has been modest.

Disclosure: Jodor Jalit holds no position in any of the mentioned stocks. 

Recommended Reading:

Guggenheim Director Makes a Buy

A Verastem Board Member Bought in at $11.53

Brandywine Realty’s Howard Sipzner Takes Another Sip of Stock

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!